Overarching aims
- Improve treatment outcomes in IBD patients, by implementing a personalised medicine-based treatment strategy trial, built on a novel serum protein signature, and treating patients with a high risk of poor disease course according to a top-down algorithm.
- Develop an exploitation plan that will focus on the development of the protein signature into a diagnostic application and to explore potential additional novel biomarkers in collaboration with the Nordicbiomedical industrial sector.